A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

NCT06255223 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
Radiotherapy
Immune Checkpoint Inhibitor

Interventions

RADIATION: High-dose Radiotherapy (HDRT)
RADIATION: Low-dose Radiotherapy (LDRT)
DRUG: Anti-PD-1 monoclonal antibody

Sponsor

Jinling Hospital, China